AAIC 2021 POSTER ABSTRACTS FEATURING SIMOA® TECHNOLOGY
Registrants can access abstracts by title or number using the AAIC Mobile App
1. A HABLE Study of the Relationship of Blood-based Biomarkers of AD and Cognition Functioning in Cognitively Normal: The Impact of Ethnicity
Abstract ID: 55280
2. A new blood-based biomarker of Aβ clearance – the monocyte Aβ mid-domain assay
Abstract ID: 56346
3. A panel of novel astrocytic and synaptic biomarkers in serum and CSF for the differential diagnosis of Frontotemporal dementia
Abstract ID: 51338
4. Alterations in white matter integrity in cognitively stable Down syndrome correlate with plasma neurofilament light chain; evidence of early myelin breakdown.
Abstract ID: 56379
5. Assessment of AD Related Plasma Biomarkers in Diverse Ancestral Populations
Abstract ID: 56258
6. Association of Plasma neurofilament light with Cognition, Cortical atrophy, Amyloid and Tau PET in cognitive impaired patients
Abstract ID: 55915
7. Association of deep-learning-derived brain computed tomography measures with cognition and blood-based biomarkers of neurodegenerative diseases
Abstract ID: 55910
8. Associations of fully automated Elecsys CSF and novel plasma biomarkers with Alzheimer’s disease neuropathology
Abstract ID: 53735
9. Associations of plasma neurofilament light protein levels with cognitive functions and brain structure parameters
Abstract ID: 55922
10. Associations of smoking and biohazard exposure with Alzheimer’s Disease brain and plasma biomarkers in early old age.
Abstract ID: 56627
11. Aβ42/Aβ40 ratio in plasma predicts amyloid-PET status in amnestic-MCI patients
Abstract ID: 57231
12. Blood Markers of Neuronal/Axonal and Glial Injury for Clinical Progression in a Predominately Hispanic Cohort: the Texas Alzheimer’s Research and Care Consortium
Abstract ID: 54270
13. Brain Atrophy and White Matter Hyperintensities are Independently Associated with Plasma Neurofilament Light Chain in an Asian Cohort of Patients with Mixed Pathology
Abstract ID: 52868
14. CS6253 ABCA1 AGONIST IN CYNOMOLGUS MONKEYS INCREASE APOA-I SUBSPECIES PREβ-HDL AND LOWERS Aβ42 AND Aβ40 IN CEREBRO SPINAL FLUID
Abstract ID: 56218
15. CSF Aβ42 and Aβ40 and their relation to brain soluble and insoluble Aβ in the 5xFAD mouse model of Alzheimer’s disease
Abstract ID: 55684
16. CSF SNAP-25 dynamics in healthy aging and across the spectrum of Alzheimer’s Disease
Abstract ID: 57662
17. Clinical and analytical comparison of three assays for plasma P-tau isoforms on an ultrasensitive platform
Abstract ID: 54044
18. Comparison of Plasma and CSF Biomarkers Across Ethnoracial Groups in ADNI
Abstract ID: 56590
19. Data-driven approach for early detection of pathological pathways in middle-aged adults with family history of sporadic Alzheimer’s disease
Abstract ID: 57768
20. Development and Validation of a High Sensitivity Assay for Measuring p217+tau in Plasma
Abstract ID: 54406
21. Development and analytical characterization of novel tau Simoa assays targeting full-length tau in CSF and mid-tau in CSF and plasma
Abstract ID: 54911
22. Diagnostic accuracy of the monocyte Aβ mid-domain assay for CSF determined brain amyloid deposition.
Abstract ID: 56435
23. Differential cognitive correlates of tau and neurofilament light chain in cerebrospinal fluid of frontotemporal lobar degeneration patients with and without Alzheimer’s markers
Abstract ID: 56446
24. Distinctive effect of biological sex in AD-related CSF and plasma biomarkers
Abstract ID: 52959
25. Evaluation of Class C CpG ODN Efficacy and Safety Profile in a Squirrel Monkey Model of AD Pathology.
Abstract ID: 55028
26. Factors associated with levels of plasma markers of amyloid pathology and neurodegeneration in a population-based sample
Abstract ID: 51720
27. Granulocyte-Macrophage Colony-Stimulating Factor Reverses Alzheimer’s Disease Pathology in the TgF344-AD Rat Model
Abstract ID: 56289
28. Interaction of Obstructive Sleep Apnea Severity and amyloid burden on novel plasma biomarkers of Tau and neurofilament light protein in community-dwelling cognitively normal older-adults
Abstract ID: 55491
29. Levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin are selectively increased in the cerebrospinal fluid of patients with Alzheimer’s Disease
Abstract ID: 56339
30. Longitudinal characterization of mild cognitive impairment and dementia in World Trade Center responders at midlife
Abstract ID: 55823
31. Longitudinal plasma Alzheimer’s disease biomarkers in an Alzheimer’s Disease Research Center cohort suggest pTau181 as the most reliable plasma biomarker for brain Alzheimer’s pathology.
Abstract ID: 55953
32. MASS SPECTROMETRIC MEASUREMENT OF SIX SITE-SPECIFIC TAU PHOSPHORYLATIONS IN CSF AND BLOOD OF ALZHEIMER´S DISEASE PATIENTS
Abstract ID: 55985
33.Neuropsychological correlates of plasma NfL in adults with Down syndrome
Abstract ID: 52881
34. Plasma biomarkers of neurodegeneration and neuroinflammantion in hospitalized COVID-19 patients with and without new neurological symptoms
Available July 29, 2021 at 1:00 pm MDT
35.Plasma P-tau181 and NfL are central nodes in a network of diagnostic, biomarker, and demographic data.
Abstract ID: 52669
36. Plasma P-tau181 levels predict amyloid pathology in cognitively unimpaired individuals after 10 years
Abstract ID: 51727
37. Plasma and CSF biomarkers for Alzheimer’s Disease Among Caribbean Hispanics
Abstract ID: 57653
38. Plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients
Abstract ID: 55520
39. Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer’s disease
Abstract ID: 50187
40. Plasma glial fibrillary acidic protein is an early and specific marker of amyloid-β pathology in Alzheimer’s disease
Abstract ID: 55538
41. Plasma neurofilament light chain (NfL) relates to preclinical changes in cognition, structural white matter integrity and markers of cerebral small-vessel disease: a population-based study
Abstract ID: 53611
42. Plasma p-tau231 in the Alzheimer’s disease continuum: a multi-cohort evaluation of diagnostic performance, detection of Aβ pathology and preclinical application
Abstract ID: 56186
43. Plasma p217+tau concordance with 18F-NAV4694 beta-amyloid and 18F-MK6240 tau PET in mild Alzheimer’s disease and cognitively unimpaired participants in the AIBL/ADNeT cohort.
Abstract ID: 55706
44. Plasma pTau isoform assessment across disease stages
Abstract ID: 50710
45. Pre-analytical and clinical validation on the highway to implementation of novel dementia blood tests
Abstract ID: 50709
46. REGULATION OF INTRACELLULAR INNATE IMMUNE AMYLOID BETA (Aβ) CLEARANCE
Abstract ID: 56329
47. Racial differences in plasma and CSF AD biomarkers show lower p-tau181 in African Americans compared to Whites
Abstract ID: 56514
48. SavaDx, a novel plasma biomarker to detect Alzheimer’s disease, confirms mechanism of action of simufilam
Abstract ID: 54385
49. Sex differences in levels of plasma neurofilament light and total tau in adults with Down Syndrome
Abstract ID: 55785
50. Stability of the novel blood-based biomarkers under pre-analytical sample handling conditions: results of the SABB-GBSC working group.
Abstract ID: 55441
51. Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer’s continuum
Abstract ID: 55448
52. The NeuroMET project: Metrology and innovation for early diagnosis and accurate stratification of patients with neurodegenerative diseases
Abstract ID: 53655
53. The association between plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light and clinical AD risk: results from prospective cohort study followed over 17 years
Abstract ID: 57547
54.
The impact of cerebrovascular disease on blood-based biomarkers of Alzheimer’s disease
Abstract ID: 55434
55. Utility of Combined Plasma Amyloid Beta 40, Amyloid Beta 42, Total Tau, and NfL along with a Measure of Cognitive Functioning in Detecting Cognitive Impairment among Hispanic, Mexican Americans Compared to Non-Hispanic Whites
Abstract ID: 56344
56. Utility of Total Tau as a Biomarker for Alzheimer’s Disease among adults with Down Syndrome
Abstract ID: 52886
57. Vascular and Inflammatory Plasma Biomarkers Correlate with Human Post-Mortem Cerebral Vascular Pathology
Abstract ID: 52379
58. Baseline plasma total tau predicts longitudinal cognitive and functional decline in aging adults
Abstract ID: 55665
59. Plasma biomarker profiles and the association with cognitive function across the clinical spectrum of Alzheimer’s disease
Abstract ID: 52167
60. Matrix Metalloproteinase-10 as a novel biomarker of neurodegeneration in Alzheimer’s disease
Abstract ID: 56323
61. Stability of blood-based biomarkers of cognitive impairment
Abstract ID: 52733
62. A Comparison of Multiple Platforms for Quantifying ATN Values in Cerebrospinal Fluid
Abstract ID: 56321
63. Association of tau pathology and vascular risk factor burden with longitudinal measures of plasma neurofilament light
Abstract ID: 56631
64. Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early AD
Abstract ID: 56164
65. A multimodal study on the effect of sex on Alzheimer’s disease clinical and biomarker changes in adults with Down syndrome
Abstract ID: 55499
66. Biomarker driven enrichment strategies for tau pathology in AD clinical trials
Abstract ID: 55656
67. Blood phosphorylated tau 181 predicts early, preclinical brain amyloid deposition
Abstract ID: 55485
68. CSF amyloid-beta, tau, neurodegenerative, and inflammatory biomarkers in cognitively unimpaired late middle-aged & older adult APOE ε4 homozygotes, heterozygotes, & non-carriers from the Arizona APOE Cohort
Abstract ID: 57242
69. Comparison of the prognostic value of cerebrospinal fluid and plasma neurofilament light in predicting longitudinal decline in white matter integrity among older adults
Abstract ID: 54958
70. Complement and NfL associations with brain structure and functional connectivity alterations in presymptomatic and symptomatic GRN mutation carriers
Abstract ID: 50737
71. Creatinine and body mass index influence on plasma amyloid ratio, p-tau217 and neurofilament light
Abstract ID: 57769
72. Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers
Abstract ID: 52117
73. Disease progression models of familial frontotemporal lobar degeneration and the temporal ordering of biomarker changes in an international cohort
Abstract ID: 55353
74. From brain volumes to subgroup classification in genetic mutation carriers for frontotemporal dementia: a cluster analysis in the GENFI study
Abstract ID: 52189
75. Individualized diagnostic and prognostic blood-based models for use in clinical practice and trials
Abstract ID: 50712
76. Longitudinal changes of phosphorylated tau 181 and neurofilament light chain in plasma and their associations with tau- and amyloid-PET
Abstract ID: 52940
77. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up
Abstract ID: 57889
78. Plasma NfL trajectory during ICU-treatment of COVID-19 patients – a prospective cohort study
Abstract ID: 57841
79. Plasma and cerebrospinal fluid neurofilament light protein concentrations are differentially associated with biomarker evidence of neurodegeneration in a community-based population of 70-year olds
Abstract ID: 53565
80. Plasma biomarkers of Alzheimer’s disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly
Abstract ID: 52909
81. Plasma biomarkers predict longitudinal amyloid accumulation, tau burden, brain atrophy and cognitive decline in early Alzheimer’s disease
Abstract ID: 55597
82. Plasma neurofilament light predicted future declines in cognition and function in Alzheimer’s disease in the FIT-AD Trial
Abstract ID: 51891
83. Role of plasma ptau181, neurofilament light, and subjective cognitive decline in predicting progression to MCI in older adults from the Alzheimer’s Disease Neuroimaging Initiative
Abstract ID: 52497
84. Serum immunoglobulins and biomarkers of dementia: a population-based study
Abstract ID: 54512
85. Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer’s disease
Abstract ID: 55011
86. Subacute plasma neurofilament light predicts neurodegeneration after moderate-severe traumatic brain injury
Abstract ID: 52522
87. The association between retinal neurodegeneration and plasma neurofilament light chain: a population-based study
Abstract ID: 51389
88. Clustering Biomarkers in Dominantly Inherited Alzheimer’s Disease
Abstract ID: 52149
89. How to define ‘N’ in the ATN classification in subjective cognitive decline: the SCIENCe project
Abstract ID: 55891